Neoadjuvant treatment with trastuzumab and folfox induces a complete pathologic response in a metastatic ERBB2 (HER2)-Amplified Duodenal Cancer

Ahmad Hamad, Aatur D. Singhi, Nathan Bahary, Kevin McGrath, Rula Amarin, Herbert J. Zeh, Amer H. Zureikat

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Overexpression of HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has been successfully applied to gastric and colorectal cancers, but its use and potential benefit in small intestinal carcinomas is not well characterized. We applied anti-HER2 therapy to an ERBB2-amplified advanced duodenal adenocarcinoma, adding trastuzumab to FOLFOX in the neoadjuvant setting. A 61-year-old woman with an advanced duodenal cancer harboring an ERBB2 amplification received preoperative trastuzumab and FOLFOX. Restaging revealed significant tumor downstaging with no metastasis. After multidisciplinary assessment, she underwent pancreaticoduo-denectomy. Final pathologic analysis revealed no residual invasive adenocarcinoma, consistent with a complete neoadjuvant treatment response. This case report emphasizes the need for further molecular characterization of small bowel cancers; genetic alterations may provide therapeutic targets to improve the prognosis of these rare and aggressive malignancies.

Original languageEnglish (US)
Pages (from-to)983-988
Number of pages6
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume15
Issue number8
DOIs
StatePublished - Aug 2017
Externally publishedYes

Fingerprint

Duodenal Neoplasms
Neoadjuvant Therapy
Adenocarcinoma
Intestinal Neoplasms
Gene Amplification
Therapeutics
Stomach Neoplasms
Colorectal Neoplasms
Neoplasms
Neoplasm Metastasis
Carcinoma
Survival
Trastuzumab
Proteins

ASJC Scopus subject areas

  • Oncology

Cite this

Neoadjuvant treatment with trastuzumab and folfox induces a complete pathologic response in a metastatic ERBB2 (HER2)-Amplified Duodenal Cancer. / Hamad, Ahmad; Singhi, Aatur D.; Bahary, Nathan; McGrath, Kevin; Amarin, Rula; Zeh, Herbert J.; Zureikat, Amer H.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 15, No. 8, 08.2017, p. 983-988.

Research output: Contribution to journalArticle

Hamad, Ahmad ; Singhi, Aatur D. ; Bahary, Nathan ; McGrath, Kevin ; Amarin, Rula ; Zeh, Herbert J. ; Zureikat, Amer H. / Neoadjuvant treatment with trastuzumab and folfox induces a complete pathologic response in a metastatic ERBB2 (HER2)-Amplified Duodenal Cancer. In: JNCCN Journal of the National Comprehensive Cancer Network. 2017 ; Vol. 15, No. 8. pp. 983-988.
@article{e1bdcf5709d442638e0058db83d26836,
title = "Neoadjuvant treatment with trastuzumab and folfox induces a complete pathologic response in a metastatic ERBB2 (HER2)-Amplified Duodenal Cancer",
abstract = "Overexpression of HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has been successfully applied to gastric and colorectal cancers, but its use and potential benefit in small intestinal carcinomas is not well characterized. We applied anti-HER2 therapy to an ERBB2-amplified advanced duodenal adenocarcinoma, adding trastuzumab to FOLFOX in the neoadjuvant setting. A 61-year-old woman with an advanced duodenal cancer harboring an ERBB2 amplification received preoperative trastuzumab and FOLFOX. Restaging revealed significant tumor downstaging with no metastasis. After multidisciplinary assessment, she underwent pancreaticoduo-denectomy. Final pathologic analysis revealed no residual invasive adenocarcinoma, consistent with a complete neoadjuvant treatment response. This case report emphasizes the need for further molecular characterization of small bowel cancers; genetic alterations may provide therapeutic targets to improve the prognosis of these rare and aggressive malignancies.",
author = "Ahmad Hamad and Singhi, {Aatur D.} and Nathan Bahary and Kevin McGrath and Rula Amarin and Zeh, {Herbert J.} and Zureikat, {Amer H.}",
year = "2017",
month = "8",
doi = "10.6004/jnccn.2017.0140",
language = "English (US)",
volume = "15",
pages = "983--988",
journal = "Journal of the National Comprehensive Cancer Network : JNCCN",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "8",

}

TY - JOUR

T1 - Neoadjuvant treatment with trastuzumab and folfox induces a complete pathologic response in a metastatic ERBB2 (HER2)-Amplified Duodenal Cancer

AU - Hamad, Ahmad

AU - Singhi, Aatur D.

AU - Bahary, Nathan

AU - McGrath, Kevin

AU - Amarin, Rula

AU - Zeh, Herbert J.

AU - Zureikat, Amer H.

PY - 2017/8

Y1 - 2017/8

N2 - Overexpression of HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has been successfully applied to gastric and colorectal cancers, but its use and potential benefit in small intestinal carcinomas is not well characterized. We applied anti-HER2 therapy to an ERBB2-amplified advanced duodenal adenocarcinoma, adding trastuzumab to FOLFOX in the neoadjuvant setting. A 61-year-old woman with an advanced duodenal cancer harboring an ERBB2 amplification received preoperative trastuzumab and FOLFOX. Restaging revealed significant tumor downstaging with no metastasis. After multidisciplinary assessment, she underwent pancreaticoduo-denectomy. Final pathologic analysis revealed no residual invasive adenocarcinoma, consistent with a complete neoadjuvant treatment response. This case report emphasizes the need for further molecular characterization of small bowel cancers; genetic alterations may provide therapeutic targets to improve the prognosis of these rare and aggressive malignancies.

AB - Overexpression of HER2 protein and amplification of the ERBB2 gene has been observed in various adenocarcinomas, providing a therapeutic target that can be used to extend the survival of a select cohort of patients. Anti-HER2 therapy has been successfully applied to gastric and colorectal cancers, but its use and potential benefit in small intestinal carcinomas is not well characterized. We applied anti-HER2 therapy to an ERBB2-amplified advanced duodenal adenocarcinoma, adding trastuzumab to FOLFOX in the neoadjuvant setting. A 61-year-old woman with an advanced duodenal cancer harboring an ERBB2 amplification received preoperative trastuzumab and FOLFOX. Restaging revealed significant tumor downstaging with no metastasis. After multidisciplinary assessment, she underwent pancreaticoduo-denectomy. Final pathologic analysis revealed no residual invasive adenocarcinoma, consistent with a complete neoadjuvant treatment response. This case report emphasizes the need for further molecular characterization of small bowel cancers; genetic alterations may provide therapeutic targets to improve the prognosis of these rare and aggressive malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85027261460&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027261460&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2017.0140

DO - 10.6004/jnccn.2017.0140

M3 - Article

C2 - 28784859

AN - SCOPUS:85027261460

VL - 15

SP - 983

EP - 988

JO - Journal of the National Comprehensive Cancer Network : JNCCN

JF - Journal of the National Comprehensive Cancer Network : JNCCN

SN - 1540-1405

IS - 8

ER -